Why Anacor Pharmaceuticals Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Anacor Pharmaceuticals has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Anacor and see what CAPS investors are saying about the stock right now.
Anacor facts
Headquarters (founded) | Palo Alto, Calif. (2000) |
Market Cap | $422.6 million |
Industry | Biotechnology |
Trailing-12-Month Revenue | $10.9 million |
Management | CEO David Perry (since 2002) |
Return on Capital (average, past 3 years) | (105.7%) |
Cash/Debt | $45.8 million / $27.7 million |
Competitors | Novartis |
Sources: S&P Capital IQ and Motley Fool CAPS.
Just yesterday, All-Star zzlangerhans touched on Anacor's seemingly unsustainable valuation:
[T]avaborole is likely to be an also-ran to Valeant's efinaconazole which has a substantially higher cure rate in phase III trials. Tavabarole is likely to be approved, but revenues will almost certainly be disappointing. A similar fate may await atopic dermatitis drug AN2728, which is yet to begin phase III trials but was only modestly efficacious in phase II.
As always, when a stock runs like this and attracts pumpers and momo traders I have no idea where the upward trajectory will end. Good chance I go deep into the red here, but a better chance I come out green in the end.
While you can certainly make quick gains in speculative biotech stocks, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Anacor Pharmaceuticals Is Poised to Pull Back originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
